Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection
- 1 December 2002
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 123 (6), 1831-1838
- https://doi.org/10.1053/gast.2002.37058
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology, 2001
- Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B VirusAntimicrobial Agents and Chemotherapy, 1999
- In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and LobucavirAntimicrobial Agents and Chemotherapy, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment.The Journal of Infectious Diseases, 1998
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Dynamics of hepatitis B virus infection in vivoJournal of Hepatology, 1997
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993